Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 20, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that European Medicines Agency (EMA) Grants Accelerated Assessment for planned ELZONRIS Marketing Authorization Application (MAA)

NEW YORK, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
November 16, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Oral Presentation of SL-701 Phase 2 Data in Second-Line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)

NEW YORK, Nov. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
November 08, 2018 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Third Quarter 2018 Financial Results

NEW YORK, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and potential commercialization of novel oncology...
November 02, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Four ELZONRIS Presentations, Including an Oral Presentation, at Upcoming ASH Meeting

NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics,...
October 16, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces SL-701 and SL-801 Clinical Data to be Featured, Including an Oral Presentation, at Upcoming ESMO 2018 Congress

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that...
September 28, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 28, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
September 05, 2018 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the H.C. Wainwright 20th Annual Global Investment Conference

NEW YORK, Sept. 05, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
August 14, 2018 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today that Ivan...
August 13, 2018 06:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that FDA Accepts ELZONRIS™ Biologics License Application (BLA) and Grants Priority Review

Conference call on BLA acceptance and commercial readiness scheduled for Monday, August 13, 2018 at 8:30 AM ET NEW YORK, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:...
August 09, 2018 08:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2018 Financial Results

NEW YORK, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a clinical-stage biopharmaceutical company developing novel oncology therapeutics, announced today its...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right